Theses

Open a thesis for its framework, payer economics, prescriber and patient view, and focus areas.

Adherence-friendly MOAs

Same patient, same nonadherence, smaller cumulative burden. Mechanisms whose effect survives missed doses decouple the body's exposure from the patient's behavior.

15 areas6 whitespaces3 proven precedents

Open thesis

Lp(a) lowering race

Coming Soon

Residual cardiovascular risk with no approved therapy. Pelacarsen's outcomes miss (Sep 2026) put the mechanism-to-outcome question front and center ahead of the siRNA readouts.

pelacarsen · olpasiran · lepodisiran · muvalaplin

Factor XI anticoagulation

Coming Soon

Anticoagulation without the DOAC bleeding cap. Also the clearest forgiving-MOA test case in AFib: monthly antibody versus daily oral.

abelacimab · milvexian · asundexian

Advanced-CKD CKM whitespace

Coming Soon

Where SGLT2 and RAAS fade with kidney function, a kidney-function-independent mechanism wins. TAM model built previously.

SGLT2 blind spot · gut-acting successors

ARDX / NHE3 platform

Coming Soon

Three-layer value stack: tenapanor revenue floor, RDX10531 as a same-mechanism exclusivity reset, and a CKM outcomes option for a large acquirer.

tenapanor · RDX10531 · ESRD bundle

APOL1 precision nephrology

Coming Soon

First causal-gene mechanism in kidney disease against symptomatic-only incumbents. Accelerated-approval setup via interim analysis.

Vertex inaxaplin · AMPLITUDE

clinical2commercial · personal research reference · not investment or medical advice